Study Result Summary
| Restaging | |||||||
| Result | Initial staging: treatment-naïve | After ADT | After surgery, PSA < 0.2 | After RT, PSA < nadir + 2 | Other primary treatment | Advanced disease | Full cohort |
| Detection rate | 30/30 (100%) | 16/16 (100%) | 1/13 (8%) | 19/22 (86%) | 13/13 (100%) | 86/103 (84%) | 166/197 (84%) |
| Number of miT1 (% by subgroup) | 29 (97%) | 15 (94%) | 0 (0%) | 13 (59%) | 10 (77%) | 27 (26%) | 95 (48%) |
| Number of miN1 (% by subgroup) | 11 (38%) | 8 (47%) | 0 (0%) | 4 (18%) | 3 (23%) | 48 (47%) | 71 36% |
| Number of miM1 (% by subgroup) | M1a: 5 (17%) | M1a: 3 (18%) | M1a: 0 (0%) | M1a: 4 (18%) | M1a: 1 (8%) | M1a: 40 (39%) | M1a: 51 (26%) |
| M1b: 4 (14%) | M1b:6 (35%) | M1b: 1 (8%) | M1b: 4 (18%) | M1b: 3 (23%) | M1b: 57 (55%) | M1b: 75 (38%) | |
| M1c: 0 | M1c: 1 (6%) | M1c: 0 (0%) | M1c: 0 | M1c: 1 (8%) | M1c: 11 (11%) | M1c: 13 (7%) | |
| Change in stage | Change: 67% | Change: 81% | Change: 38% | Change: 86% | Change: 69% | Change: 67% | Change: 69% |
| No change: 33% | No change: 19% | No change: 62% | No change: 14% | No change: 31% | No change: 33% | No change: 31% | |
| Change in management* (%) | 12/28 (43%) | 6/15 (40%) | 6/13 (46%) | 13/18 (72%) | 8/12 (67%) | 59/96 (61%) | 104/182 (57%) |
↵* Change-in-management analysis was conducted on 182 patients.
Molecular imaging TNM classification: T = PSMA uptake in prostate gland or prostate bed or prostatic fossa; N = PSMA uptake in pelvic lymph nodes; M = PSMA uptake in distant lymph nodes (M1a), bone (M1b), or other visceral organs (M1c).